Homechevron_rightAll Peptideschevron_rightRetatrutide

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-retatrutide-10mg

Official Product Data Sheet

Retatrutide (10mg)

Ultra High >99.5% Purity

Vial Contents

10 mg Retatrutide (lyophilized powder)

Includes

3 ml bacteriostatic water for reconstitution

Form

Lyophilized white powder for optimal stability

Purity

≥98%, third-party tested (COA available)

Sequence

Long-acting triple agonist (proprietary structure)

Molecular Formula

C₂₂₃H₃₄₃N₅₃O₇₀S₂

Molecular Mass

~4731 g/mol

CAS No.

2381089-83-2

Solubility

Reconstitute with sterile/bacteriostatic water (3 ml for ~3.33 mg/mL)

Storage

Lyophilized frozen; reconstituted refrigerated at 2–8°C for up to 28 days

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Europe

local_shipping1-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Retatrutridekopen.com

Europe

local_shipping3-5 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

Scientific Background

This groundbreaking triple agonist is transforming weight loss journeys, with clinical trials showing up to 24% body weight reduction in just 48 weeks—results that rival bariatric surgery.

Retatrutide is a long-acting triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors, delivering unmatched weight loss and metabolic benefits.

By activating three key hormones at once, Retatrutide crushes appetite, ramps up fat burning, and increases energy expenditure—leading to dramatic, sustainable weight loss. The glucagon boost burns calories like exercise—perfect for stubborn fat that won't budge.

Intended Research Use

Drives massive weight loss (up to 24% in trials)
Melts visceral fat and improves liver health (82% reduction)
Boosts insulin sensitivity and energy levels
Drops HbA1c by ~2% in diabetes
Improves blood pressure and lipid profiles

menu_bookScientific Publications

article

N Engl J Med (2023)

Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37366315/

article

Lancet (2023)

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37364343/

article

Nat Med (2024)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/38877164/

Clinical Evidence: Phase 3 trials prove it: participants lost 11–24% body weight over 48 weeks, with many dropping ≥15%—far beyond diet/exercise alone. In type 2 diabetes, it slashed HbA1c by ~2% while shedding ~17kg. The triple action crushes hunger, burns fat faster, and protects your liver.

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Clinical research suggests combining Retatrutide with complementary peptides can enhance weight management outcomes. These combinations target multiple metabolic pathways for amplified fat-burning effects.

Cagrilintide

arrow_forward

myo-cagrilintide-5mg

Supercharges satiety for even faster weight loss through amylin-analog synergy.

AOD-9604

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Targets stubborn fat pockets while Retatrutide handles overall metabolism.

Semaglutide

arrow_forward

myo-semaglutide-5mg

Amplifies GLP-1 effects for maximum appetite control and fat burn.

schedule

Cycling Note: Once-weekly subcutaneous for minimum 12 weeks (trials up to 48 weeks). Continue for ongoing fat loss results.